Roche says early-stage obesity pill results were based on just six patients
Adds detail of trial in paragraph 6, company comment in paragraph 7, further detail in paragraphs 8-10
FRANKFURT, Sept 11 (Reuters) -Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
The Swiss drugmaker said in July that the once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in a Phase I trial.
Presentation slides published on Wednesday showed that while the trial involved 25 participants overall - six of which were given an ineffective placebo for comparison - the result summary was taken from the best-performing of the three other subgroups on the experimental treatment.
The second-best-performing subgroup, which had seven volunteers, reached an average placebo-adjusted weight loss of 4.6%, the data showed.
The company reiterated that larger trials in the second of three development stages would start next year.
It said the Phase I trial followed a convention of ramping up the drug dose, a process known as titration, faster than is planned during later trial stages, in order to uncover any unforeseen side effects early.
"These data support the continued investigation of CT-996 in studies of longer duration with larger sample sizes and slower titrations," the company said in a presentation held at a meeting of the European Association for the Study of Diabetes in Madrid.
Roche in December agreed to take over the drug's developer Carmot for $2.7 billion upfront, joining the race to challenge the dominant makers of weight-loss injections Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.
The emerging new generation of gut-hormone drugs for weight loss, which some analysts predict will generate $150 billion by the early 2030s, are initially given at low starter doses and the concentration of active ingredient is then increased over weeks or months.
The best-performing subgroup in Roche's trial was one of two cohorts where the dose ramp-up ended at 120 mg of CT-996 per day, while a third cohort ended at 90 mg.
Reporting by Ludwig Burger; Editing by Matthias Williams and Jan Harvey
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.